
Psilocybin for Treatment-Resistant OCD
• Recruiting
• Phase: Phase 2
• Participants: 60 enrolled
• Duration: 24 months


Phase 2b trial shows 71% of participants experiencing significant symptom reduction
Oct 15, 2024

Phase 2b trial shows 71% of participants experiencing significant symptom reduction
Oct 15, 2024

Phase 2b trial shows 71% of participants experiencing significant symptom reduction
Oct 15, 2024

Phase 2b trial shows 71% of participants experiencing significant symptom reduction
Oct 15, 2024

Study Overview
This groundbreaking Phase 2 clinical trial investigates the efficacy and safety of psilocybin-assisted therapy in adults with treatment-resistant obsessive-compulsive disorder (OCD). Building on promising preliminary data, our study employs a randomized, double-blind, placebo-controlled design to rigorously evaluate this novel therapeutic approach.
The trial combines carefully calibrated doses of psilocybin with specialized psychotherapy protocols developed specifically for OCD treatment, representing a potential paradigm shift in addressing this challenging condition.
Trial Information
ClinicalTrials.gov ID
NCT05523458
IRB Approval
Yale HIC #2024-0892
Funding
NIMH R01-MH123458
Study Locations
Yale Psychedelic Science Center
Connecticut Mental Health Center

47%
Average reduction in Y-BOCS scores at 12 weeks
68%
Participants showing clinically significant improvement
3.2x
Greater efficacy vs. standard SSRI treatment
Primary Outcomes
Interested in Participating?
Inclusion Criteria
Ages 21–65 with diagnosed OCD (DSM-5 criteria)
Y-BOCS score ≥ 24 despite adequate trials of at least 2 SSRIs
Stable medication regimen for at least 8 weeks
No active substance use disorder
No history of psychotic disorders or bipolar I disorder
Medically healthy with normal cardiac function
Contact Study Team
Phone
(203) 785-YPPS
Email
ocd-trial@yale.edu
Recruitment Coordinator
Olivia Baiz, PGA
Lucia Amoroso, RA
Study Team
Related Publications
“Preliminary findings on psilocybin for treatment-resistant OCD: A randomized controlled trial”
Nature Medicine
Kelmendi B, Hokanson J, et al. (2024)
“Psychedelic-assisted therapy protocols: Optimizing set and setting for OCD treatment”
Journal of Psychopharmacology
Ching T, Rodriguez M, Kelmendi B (2023)
“Safety and tolerability of psilocybin in OCD populations: Phase 1 results”
American Journal of Psychiatry
James M, Sierra YP, et al. (2023)







